Ipilimumab, which inhibits cytotoxic T-lymphocyte-associated antigen 4 was shown to provide survival advantage, with or without a gp100 peptide vaccine, as compared with gp100 alone, in patients with previously treated metastatic melanoma in 2010;[17]. The gene discussed is CTLA4; the disease is metastatic melanoma.